Hyunsung Kim

Prof. Hyunsung Kim

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
HKHyun Young Kim
Hyun Young Kim
YCYoung Jae Choi
Young Jae Choi
SKSang Kyum Kim
Sang Kyum Kim
HKHyunsung Kim
Hyunsung Kim
DJDae Won Jun
Dae Won Jun
KKKeon Wook Kang
Keon Wook Kang
Demand for a cure of liver fibrosis is rising with its increasing morbidity and mortality. Therefore, it is an urgent issue to investigate its therapeutic candidates. Liver fibrosis progresses following ‘multi-hit’ processes involving hepatic stellate cells, macrophages, and hepatocytes. The NOD-like receptor protein 3 (NLRP3) inflammasome is emerging as a therapeutic target in liver fibrosis. Previous studies showed that the anti-rheumatic agent auranofin inhibits the NLRP3 inflammasome; thus, this study evaluates the antifibrotic effect of auranofin in vivo and explores the underlying molecular mechanism. The antifibrotic effect of auranofin is assessed in thioacetamide- and carbon tetrachloride-induced liver fibrosis models. Moreover, hepatic stellate cell (HSC), bone marrow-derived macrophage (BMDM), kupffer cell, and hepatocyte are used to examine the underlying mechanism of auranofin. Auranofin potently inhibits activation of the NLRP3 inflammasome in BMDM and kupffer cell. It also reduces the migration of HSC. The underlying molecular mechanism was inhibition of cystine-glutamate antiporter, systemXc. Auranofin inhibits systemXcactivity and instantly induced oxidative burst, which mediated inhibition of the NLRP3 inflammasome in macrophages and HSCs. Therefore, to the best of our knowledge, we propose the use of auranofin as an anti-liver fibrotic agent.

5 January 2022 in Life
Verified
Journal Article
Open access
PDF file
HKHyunsung Kim
Hyunsung Kim
YKYoung Hyeh Ko
Young Hyeh Ko
Extranodal NK/T-cell lymphoma is a neoplasm of NK cells or cytotoxic T cells presenting in extranodal sites, most often in the nasal cavity. The typical immunophenotypes are cCD3+, sCD3−, CD4−, CD5−, CD8−, CD16−, and CD56+ with the expression of cytotoxic molecules. Tumor subsets express NK cell receptors, CD95/CD95L, CD30, MYC, and PDL1. Virtually all the tumor cells harbor the EBV genome, which plays a key role in lymphomagenesis as an epigenetic driver. EBV-encoded oncoproteins modulate the host-cell epigenetic machinery, reprogramming the viral and host epigenomes using host epigenetic modifiers. NGS analysis revealed the mutational landscape of ENKTL, predominantly involving the JAK–STAT pathway, epigenetic modifications, the RNA helicase family, the RAS/MAP kinase pathway, and tumor suppressors, which indicate an important role of these pathways and this group of genes in the lymphomagenesis of ENKTL. Recently, three molecular subtypes were proposed, the tumor-suppressor/immune-modulator (TSIM), MGA-BRDT (MB), and HDAC9-EP300-ARID1A (HEA) subtypes, and they are well-correlated with the cell of origin, EBV pattern, genomic alterations, and clinical outcomes. A future investigation into the function and interaction of discovered genes would be very helpful for better understanding the molecular pathogenesis of ENKTL and establishing better treatment strategies.

23 June 2020 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
HKHyunsung Kim
Hyunsung Kim
SBSeongsik Bang
Seongsik Bang
SJSeungyun Jee
Seungyun Jee
SPSeung Sam Paik
Seung Sam Paik
KJKiseok Jang
Kiseok Jang
Aims CD47 is upregulated on the surface of various tumour cells, and it is known to inhibit the phagocytosis of tumour cells by macrophages. Immunotherapy that targets CD47 has demonstrated success in preclinical trials and is now under clinical investigation for both solid and haematological malignancies. However, data regarding CD47 expression in hepatocellular carcinoma (HCC) tissue and its correlation with clinical outcomes in patients with HCC remain limited. Here, we investigated the clinicopathological features associated with CD47 expression in HCC. Methods CD47 expression was evaluated by immunohistochemistry in tissue microarray sections containing 166 HCC tissues. CD47 expression was considered positive if 10% or more tumour cells were stained. Results CD47 expression was observed in 36 (21.7%) of 166 HCC tissues and was significantly associated with frequent large vessel invasion, advanced American Joint Committee on Cancer stage and higher Ki-67 proliferation index. In the survival analyses, CD47 expression was not associated with recurrence-free survival or overall survival in total patients with HCC. However, in patients who received surgical resection without any adjuvant treatment, CD47 expression was associated with shorter recurrence-free survival. Conclusions CD47 expression was significantly associated with adverse pathological features and poor clinical outcomes in patients with HCC who did not receive adjuvant treatment.

30 September 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
YKYeseul Kim
Yeseul Kim
HKHyunsung Kim
Hyunsung Kim
SBSeongsik Bang
Seongsik Bang
SJSeungyun Jee
Seungyun Jee
KJKiseok Jang
Kiseok Jang

1 January 2015 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
HKHyunsung Kim
Hyunsung Kim
SJSe Min Jang
Se Min Jang
HAHyein Ahn
Hyein Ahn
JSJongmin Sim
Jongmin Sim
KYKijong Yi
Kijong Yi
Seung Sam PaikSeung Sam Paik
Seung Sam Paik
Kim H, et al. J Breast Cancer. 2015 Mar;18(1):1-7. https://doi.org/10.4048/jbc.2015.18.1.1

22 August 2016 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
HKHyunsung Kim
Hyunsung Kim
YPYong Wook Park
Yong Wook Park
YOYoung-Ha Oh
Young-Ha Oh
JSJongmin Sim
Jongmin Sim
JRJae Y. Ro
Jae Y. Ro
JPJu Yeon Pyo
Ju Yeon Pyo